Who are Fulvestrant injection ;Dalpiciclib Isethionate's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fulvestrant in combination with abemaciclib.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fulvestrant-injection-dalpiciclib-isethionate.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Fulvestrant injection ;Dalpiciclib Isethionate — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Fulvestrant injection ;Dalpiciclib Isethionate (Fulvestrant injection ;Dalpiciclib Isethionate) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective estrogen receptor degrader (SERD) + CDK4/6 inhibitor combination. Area: Oncology.

phase 3 Selective estrogen receptor degrader (SERD) + CDK4/6 inhibitor combination Estrogen receptor (ER) and cyclin-dependent kinases 4/6 (CDK4/6) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Fulvestrant injection ;Dalpiciclib Isethionate (Fulvestrant injection ;Dalpiciclib Isethionate) — Shandong Suncadia Medicine Co., Ltd.. This combination uses fulvestrant to block estrogen receptors in breast cancer cells while dalpiciclib inhibits cyclin-dependent kinases 4 and 6 to prevent cell cycle progression.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Fulvestrant injection ;Dalpiciclib Isethionate TARGET	Fulvestrant injection ;Dalpiciclib Isethionate	Shandong Suncadia Medicine Co., Ltd.	phase 3	Selective estrogen receptor degrader (SERD) + CDK4/6 inhibitor combination	Estrogen receptor (ER) and cyclin-dependent kinases 4/6 (CDK4/6)
Fulvestrant in combination with abemaciclib	Fulvestrant in combination with abemaciclib	Sermonix Pharmaceuticals Inc.	phase 3	Selective estrogen receptor degrader (SERD) + CDK4/6 inhibitor combination	Estrogen receptor (ER) and CDK4/CDK6

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective estrogen receptor degrader (SERD) + CDK4/6 inhibitor combination class)

Sermonix Pharmaceuticals Inc. · 1 drug in this class
Shandong Suncadia Medicine Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fulvestrant injection ;Dalpiciclib Isethionate — Competitive Intelligence Brief. https://druglandscape.com/ci/fulvestrant-injection-dalpiciclib-isethionate. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab